Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?

• मुख्य लेखकों: Mark eWainberg (लेखक), Yingshan eHan (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2015-04-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir (RAL) and elvitegravir (EVG), DTG shows a limited cross-resistance profile. More interestingly, clinica...